Biotechnological approaches to the production of idiotypic vaccines and antiidiotypic antibiotics

W. Magliani, S. Conti, A. Salati, S. Arseni, L. Ravanetti, R. Frazzi, L. Polonelli

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

The potential therapeutic activity of a killer toxin produced by the yeast Pichia anomala (PaKT) characterized by its wide spectrum of antimicrobial activity has been exploited through the simulation of its interaction with the specific cell wall receptor (KTR) of PaKT-sensitive microorganisms by the idiotypic network. Killer antiidiotypes (PaKTantiId) produced by idiotypic vaccination with a PaKT-neutralizing monoclonal antibody have proven to confer active and passive immunoprotection in experimental models of systemic and vaginal candidiasis. PaKTantiId-like human anti-KTR antibodies are naturally produced in infections caused by PaKT-sensitive microorganisms. PaKTantiId in its monoclonal and recombinant formats as well as expressed on human commensal bacteria have shown microbicidal activity in vitro and a therapeutic effect in experimental models of infection caused by PaKT-sensitive microorganisms. New perspectives of idiotypic vaccination and antiidiotypic antibiotic therapy and biotechnological approaches to the production of trandisease idiotypic vaccines and wide-spectrum antiidiotypic antibiotics (killer mimotopes) will be discussed as effective tools to fight epidemiologically important mucosal and systemic microbial infections.

Original languageEnglish
Pages (from-to)91-97
Number of pages7
JournalCurrent Pharmaceutical Biotechnology
Volume4
Issue number2
DOIs
Publication statusPublished - Apr 2003

Fingerprint

Vaccines
Anti-Bacterial Agents
Yeast Killer Factor
Vaccination
Theoretical Models
Infection
Pichia
Therapeutic Uses
Neutralizing Antibodies
Cell Wall
Anti-Idiotypic Antibodies
Monoclonal Antibodies
Bacteria
Therapeutics
In Vitro Techniques
Systemic candidiasis

Keywords

  • Antiidiotypic antibiotics
  • Antiidiotypic therapy
  • Idiotypic vaccines
  • Killer mimotopes
  • Transdisease vaccination
  • Yeast killer toxin

ASJC Scopus subject areas

  • Biotechnology
  • Molecular Medicine
  • Pharmaceutical Science

Cite this

Biotechnological approaches to the production of idiotypic vaccines and antiidiotypic antibiotics. / Magliani, W.; Conti, S.; Salati, A.; Arseni, S.; Ravanetti, L.; Frazzi, R.; Polonelli, L.

In: Current Pharmaceutical Biotechnology, Vol. 4, No. 2, 04.2003, p. 91-97.

Research output: Contribution to journalArticle

Magliani, W. ; Conti, S. ; Salati, A. ; Arseni, S. ; Ravanetti, L. ; Frazzi, R. ; Polonelli, L. / Biotechnological approaches to the production of idiotypic vaccines and antiidiotypic antibiotics. In: Current Pharmaceutical Biotechnology. 2003 ; Vol. 4, No. 2. pp. 91-97.
@article{43e8e79e48d64e679202d0f3418b675a,
title = "Biotechnological approaches to the production of idiotypic vaccines and antiidiotypic antibiotics",
abstract = "The potential therapeutic activity of a killer toxin produced by the yeast Pichia anomala (PaKT) characterized by its wide spectrum of antimicrobial activity has been exploited through the simulation of its interaction with the specific cell wall receptor (KTR) of PaKT-sensitive microorganisms by the idiotypic network. Killer antiidiotypes (PaKTantiId) produced by idiotypic vaccination with a PaKT-neutralizing monoclonal antibody have proven to confer active and passive immunoprotection in experimental models of systemic and vaginal candidiasis. PaKTantiId-like human anti-KTR antibodies are naturally produced in infections caused by PaKT-sensitive microorganisms. PaKTantiId in its monoclonal and recombinant formats as well as expressed on human commensal bacteria have shown microbicidal activity in vitro and a therapeutic effect in experimental models of infection caused by PaKT-sensitive microorganisms. New perspectives of idiotypic vaccination and antiidiotypic antibiotic therapy and biotechnological approaches to the production of trandisease idiotypic vaccines and wide-spectrum antiidiotypic antibiotics (killer mimotopes) will be discussed as effective tools to fight epidemiologically important mucosal and systemic microbial infections.",
keywords = "Antiidiotypic antibiotics, Antiidiotypic therapy, Idiotypic vaccines, Killer mimotopes, Transdisease vaccination, Yeast killer toxin",
author = "W. Magliani and S. Conti and A. Salati and S. Arseni and L. Ravanetti and R. Frazzi and L. Polonelli",
year = "2003",
month = "4",
doi = "10.2174/1389201033489874",
language = "English",
volume = "4",
pages = "91--97",
journal = "Current Pharmaceutical Biotechnology",
issn = "1389-2010",
publisher = "Bentham Science Publishers B.V.",
number = "2",

}

TY - JOUR

T1 - Biotechnological approaches to the production of idiotypic vaccines and antiidiotypic antibiotics

AU - Magliani, W.

AU - Conti, S.

AU - Salati, A.

AU - Arseni, S.

AU - Ravanetti, L.

AU - Frazzi, R.

AU - Polonelli, L.

PY - 2003/4

Y1 - 2003/4

N2 - The potential therapeutic activity of a killer toxin produced by the yeast Pichia anomala (PaKT) characterized by its wide spectrum of antimicrobial activity has been exploited through the simulation of its interaction with the specific cell wall receptor (KTR) of PaKT-sensitive microorganisms by the idiotypic network. Killer antiidiotypes (PaKTantiId) produced by idiotypic vaccination with a PaKT-neutralizing monoclonal antibody have proven to confer active and passive immunoprotection in experimental models of systemic and vaginal candidiasis. PaKTantiId-like human anti-KTR antibodies are naturally produced in infections caused by PaKT-sensitive microorganisms. PaKTantiId in its monoclonal and recombinant formats as well as expressed on human commensal bacteria have shown microbicidal activity in vitro and a therapeutic effect in experimental models of infection caused by PaKT-sensitive microorganisms. New perspectives of idiotypic vaccination and antiidiotypic antibiotic therapy and biotechnological approaches to the production of trandisease idiotypic vaccines and wide-spectrum antiidiotypic antibiotics (killer mimotopes) will be discussed as effective tools to fight epidemiologically important mucosal and systemic microbial infections.

AB - The potential therapeutic activity of a killer toxin produced by the yeast Pichia anomala (PaKT) characterized by its wide spectrum of antimicrobial activity has been exploited through the simulation of its interaction with the specific cell wall receptor (KTR) of PaKT-sensitive microorganisms by the idiotypic network. Killer antiidiotypes (PaKTantiId) produced by idiotypic vaccination with a PaKT-neutralizing monoclonal antibody have proven to confer active and passive immunoprotection in experimental models of systemic and vaginal candidiasis. PaKTantiId-like human anti-KTR antibodies are naturally produced in infections caused by PaKT-sensitive microorganisms. PaKTantiId in its monoclonal and recombinant formats as well as expressed on human commensal bacteria have shown microbicidal activity in vitro and a therapeutic effect in experimental models of infection caused by PaKT-sensitive microorganisms. New perspectives of idiotypic vaccination and antiidiotypic antibiotic therapy and biotechnological approaches to the production of trandisease idiotypic vaccines and wide-spectrum antiidiotypic antibiotics (killer mimotopes) will be discussed as effective tools to fight epidemiologically important mucosal and systemic microbial infections.

KW - Antiidiotypic antibiotics

KW - Antiidiotypic therapy

KW - Idiotypic vaccines

KW - Killer mimotopes

KW - Transdisease vaccination

KW - Yeast killer toxin

UR - http://www.scopus.com/inward/record.url?scp=0037388541&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037388541&partnerID=8YFLogxK

U2 - 10.2174/1389201033489874

DO - 10.2174/1389201033489874

M3 - Article

C2 - 12678884

AN - SCOPUS:0037388541

VL - 4

SP - 91

EP - 97

JO - Current Pharmaceutical Biotechnology

JF - Current Pharmaceutical Biotechnology

SN - 1389-2010

IS - 2

ER -